Pan-Asia Catalysts/Events, Quiddity Advisors

David Blennerhassett

HK Type 4 license through Ballingal Investment Advisors Ltd. 

I'm a highly experienced sell-side analyst with in excess of 22 years of covering Asia Pacific equities, the past 19 years immersed in event strategies encompassing M&A risk arbitrage, directional long/short, stub trades and restructuring.  

My background also includes accountancy (liquidation/bankruptcy/receivership) earlier in my career and as a chief financial officer of a global commodity company based in the US and Mexico.

Pan-Asia Catalysts/Events

Mayne Pharma (MYX AU): Firm Support From Cosette Would Be Welcome About Now

Quiddity Advisors

Event-Driven

<ul>
<li>
<a href="https://www.smartkarma.com/entities/mayne-pharma-group-ltd" target="_blank" data-smartkarma-citation="entities:757:1" rel="noopener"><strong>Mayne Pharma (MYX AU)</strong></a>, a leader in dermatology and women’s health, has entered into a Scheme Implementation Deed with US-based pharmaceutical outfit, Cosette Pharmaceuticals.</li>
<li>
<strong>Cosette is offering A$7.40/share</strong>, a 37% premium to last close. Apart from Mayne's shareholder approval, the Offer requires FIRB signing off. </li>
<li>The Offer also has the backing of Mayne's two largest shareholder, Viburnum and Bruce Mathieson, collectively holding 14.1%. Implementation is expected late May, early June 2025. This is done.</li>
</ul>



Mayne Pharma (MYX AU), a leader in dermatology and women’s health, has entered into a Scheme Implementation Deed with US-based pharmaceutical outfit, Cosette Pharmaceuticals.

Cosette is offering A$7.40/share, a 37% premium to last close. Apart from Mayne's shareholder approval, the Offer requires FIRB signing off. 
The Offer also has the backing of Mayne's two largest shareholder, Viburnum and Bruce Mathieson, collectively holding 14.1%. Implementation is expected late May, early June 2025. This is done.


Mayne Pharma (MYX AU): Cosette's A$7.40/Share Scheme